> top > projects > sentences > docs > PubMed:25267524 > annotations
sentences Home  

PubMed:25267524 JSONTXT 15 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-125 Sentence denotes Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
T1 0-125 Sentence denotes Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
TextSentencer_T2 126-137 Sentence denotes BACKGROUND:
T2 126-137 Sentence denotes BACKGROUND:
TextSentencer_T3 138-214 Sentence denotes Proteasome inhibitors are a relatively new class of chemotherapeutic agents.
T3 138-214 Sentence denotes Proteasome inhibitors are a relatively new class of chemotherapeutic agents.
TextSentencer_T4 215-325 Sentence denotes Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma.
T4 215-325 Sentence denotes Bortezomib is the first agent of this class and is currently being used for the treatment of multiple myeloma.
TextSentencer_T5 326-436 Sentence denotes However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy.
T5 326-436 Sentence denotes However, recent reports have linked exposure to bortezomib with the development of thrombotic microangiopathy.
TextSentencer_T6 437-575 Sentence denotes A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma.
T6 437-575 Sentence denotes A new agent in this class, carfilzomib, has been recently introduced as alternative therapy for relapsing and refractory multiple myeloma.
TextSentencer_T7 576-714 Sentence denotes We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.
T7 576-714 Sentence denotes We report a case of renal thrombotic microangiopathy associated with the use of carfilzomib in a patient with refractory multiple myeloma.
TextSentencer_T8 715-733 Sentence denotes CASE PRESENTATION:
T8 715-733 Sentence denotes CASE PRESENTATION:
TextSentencer_T9 734-935 Sentence denotes A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants.
T9 734-935 Sentence denotes A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants.
TextSentencer_T10 936-1082 Sentence denotes After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks.
T10 936-1082 Sentence denotes After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks.
TextSentencer_T11 1083-1158 Sentence denotes Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L).
T11 1083-1158 Sentence denotes Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L).
TextSentencer_T12 1159-1293 Sentence denotes Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma.
T12 1159-1293 Sentence denotes Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma.
TextSentencer_T13 1294-1410 Sentence denotes Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria.
T13 1294-1410 Sentence denotes Six weeks later, he developed abrupt worsening of lower extremity edema and hypertension, and new onset proteinuria.
TextSentencer_T14 1411-1447 Sentence denotes His kidney function remained stable.
T14 1411-1447 Sentence denotes His kidney function remained stable.
TextSentencer_T15 1448-1519 Sentence denotes Kidney biopsy findings were consistent with thrombotic microangiopathy.
T15 1448-1519 Sentence denotes Kidney biopsy findings were consistent with thrombotic microangiopathy.
TextSentencer_T16 1520-1608 Sentence denotes Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved.
T16 1520-1608 Sentence denotes Eight weeks after discontinuation of carfilzomib, proteinuria and hypertension improved.
TextSentencer_T17 1609-1676 Sentence denotes Due to progression of multiple myeloma, he died a few months later.
T17 1609-1676 Sentence denotes Due to progression of multiple myeloma, he died a few months later.
TextSentencer_T18 1677-1688 Sentence denotes CONCLUSION:
T18 1677-1688 Sentence denotes CONCLUSION:
TextSentencer_T19 1689-2070 Sentence denotes In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.
T19 1689-2070 Sentence denotes In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient.